EpiVario is a preclinical stage biotechnology company focusing on developing treatments for neuropsychiatric disorders. Our co-founders, Dr. Shelley Berger and Dr. Philipp Mews, are leaders in the field of neuroepigenetics. They identified a key metabolic enzyme, acetyl CoA synthetase (ACSS2), that functions within the nucleus of hippocampal cells to activate genes critical for long term memory. This epigenetic mechanism plays a critical role in consolidating trauma-induced fear and stress responses and drug craving associated with addiction; thus, providing a new target for treating memory-related neuropsychiatric disorders, such as PTSD and drug and alcohol addiction. Based on this paradigm-shifting finding, EpiVario is developing a pharmacotherapeutic to treat nicotine addiction. We demonstrated efficacy of an ACSS2 inhibitor in reducing drug seeking behavior in rats in a nicotine self-administration study, and plan to show safety and efficacy in a phase 1b trial by the end of 2023. Thereafter, EpiVario will initiate a public offering and/or license out the asset for nicotine addiction indication.